First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in pregnant women
Roche will access SpeeDx existing tests and technology to expand diagnostic products for the management of antibiotic resistance in STIs
The RECOVERY trial has shown that the cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19
It's comprehensive SARS-COV-2 offerings span RT-PCR, high throughput RNA extraction, automation, ELISA and lateral flow based serology testing.
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies and can guide treatment decisions for patients with Lynch-associated cancers
Company exploring further additional global capacity to provide broad and equitable access
llumina's COVIDSeq aims to generate information about the genomic sequence of the virus
Large-scale manufacturing of rapid diagnostic test kit and reagents to enable increased testing capacity for COVID-19 worldwide
LifeShare Blood Center deploys Biolog-id’s cutting-edge technology providing digital visibility to convalescent plasma containing antibodies from recovered COVID-19 patients
This aims to assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy
The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalized with COVID-19
This aims to make use of its collective and accumulated knowledge of graphene to fight the current pandemic
Total antibody test aims to deliver superior clinical performance with 100% sensitivity and 99.8% specificity
The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients
Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels
People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus
The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour
The company aims to ramp up its production capacity of more than 50 million antibody tests per month
Test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments
Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity
Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers
A qualitative test for the detection of nucleic acid from SARS-CoV-2
The COVID-19 vaccine trial is part of a global development program that will uncover the safety and immunogenicity of four mRNA vaccine candidates.
The company says it continues to optimize its coronavirus test amid questions about its accuracy
